ライフサイエンスコーパス: mycosis fungoides

1 ad chronic myelogenous leukemia, and one had mycosis fungoides.

2 tes the results to skin stage and outcome in mycosis fungoides.

3 10q and MSI in advanced cutaneous stages of mycosis fungoides.

4 arge proportion of patients with early stage mycosis fungoides.

5 ssessment of peripheral blood involvement in mycosis fungoides.

6 feature of the large-cell transformation of mycosis fungoides.

7 usly as a single dose to eight patients with mycosis fungoides.

8 red with the staging system for conventional mycosis fungoides.

9 rived from patients with Sezary syndrome and mycosis fungoides.

10 pression in lesional skin from patients with mycosis fungoides.

11 systemic treatment in patients with stage IB mycosis fungoides.

12 specially in Sezary syndrome and transformed mycosis fungoides.

13 ype may contribute to disease progression in mycosis fungoides.

14 was associated with an older age of onset of mycosis fungoides.

15 all of which were from the 44 patients with mycosis fungoides (10/44 patients; 23%).

16 s antibody (1) had clinical efficacy against mycosis fungoides; (2) was well tolerated; (3) had a low

17 n 18 patients (25%), including 12 of 57 with mycosis fungoides (21%) and six of 16 with Sezary syndro

18 Seven patients (44%) had cutaneous (all mycosis fungoides); 4 (25%) had peripheral T cell not ot

19 as found to be more prevalent in tumor stage mycosis fungoides (47%) than early stage disease (20%) a

20 patients [82.3%]), had disease classified as mycosis fungoides (48 patients [61.5%]), and had advance

21 tificates for two such cancers, melanoma and mycosis fungoides (a cutaneous lymphoma), using routinel

22 ease that recapitulates many key features of mycosis fungoides, a common variant of cutaneous T-cell

23 pendent prognostic variable in patients with mycosis fungoides after correcting for age, skin, and ly

24 er of the small intestine, eye melanoma, and mycosis fungoides, among men in a European, multicenter

25 the 54 samples (24%), 12 from patients with mycosis fungoides and 1 from a patient with Sezary syndr

26 have analyzed 51 samples from patients with mycosis fungoides and 15 with Sezary syndrome using meth

27 contributing 52% of the mutational burden in mycosis fungoides and 23% in Sezary syndrome.

28 uding losses on 9p21 in 16% of patients with mycosis fungoides and 46% with Sezary syndrome.

29 amples from 59 patients with Sezary syndrome/mycosis fungoides and 66 samples from unique patients wi

30 lic loss was present in 45% of patients with mycosis fungoides and 67% with Sezary syndrome.

31 eous T-cell lymphoma, and mogamulizumab, for mycosis fungoides and adult T-cell leukaemia/lymphoma.

32 tested SS patients but not in patients with mycosis fungoides and atopic dermatitis or HD.

33 has also shown promise in the management of mycosis fungoides and extranodal natural killer/T-cell l

34 Mycosis fungoides and its leukemic variant, Sezary syndr

35 Mycosis fungoides and Sezary syndrome (MF/SS) are rare i

36 Mycosis fungoides and Sezary syndrome (MF/SS) has an inc

37 that recapitulated the cardinal features of mycosis fungoides and Sezary syndrome and maintained his

38 common in both early and advanced stages of mycosis fungoides and Sezary syndrome and that these gen

39 Advanced mycosis fungoides and Sezary syndrome are life threateni

40 Agents targeting the unique biology of mycosis fungoides and Sezary syndrome are quickly being

41 Mycosis fungoides and Sezary syndrome are the most commo

42 Mycosis fungoides and Sezary syndrome are the most commo

43 Mycosis fungoides and Sezary syndrome are two major form

44 Although the aetiologies of mycosis fungoides and Sezary syndrome are unknown, impor

45 Guidelines for mycosis fungoides and Sezary syndrome clinical trials we

46 Mycosis fungoides and Sezary syndrome comprise the major

47 approximately 30% of patients with advanced mycosis fungoides and Sezary syndrome cutaneous T-cell l

48 aneous T-cell lymphoma (CTCL), including the mycosis fungoides and Sezary syndrome forms of the disea

49 lastic cells (Sezary cells) in patients with mycosis fungoides and Sezary syndrome is essential for d

50 ined lesional skin biopsy specimens from 113 mycosis fungoides and Sezary Syndrome patients for activ

51 lly reverse or suppress the abnormalities of mycosis fungoides and Sezary syndrome to the point at wh

52 ous T-cell lymphoma (CTCL), particularly the mycosis fungoides and Sezary syndrome variants, has been

53 276 patients with cutaneous T cell lymphoma (mycosis fungoides and Sezary syndrome) using 2,4-dinitro

54 oproliferative processes, mainly composed of mycosis fungoides and Sezary syndrome, the aggressive fo

55 inhibit malignant T cells in skin lesions in mycosis fungoides and Sezary syndrome, the most common f

56 Discoveries regarding the pathophysiology of mycosis fungoides and Sezary syndrome, the two most comm

57 candidate tumor suppressor genes involved in mycosis fungoides and Sezary syndrome.

58 h cutaneous T-cell lymphoma (CTCL) including mycosis fungoides and Sezary syndrome.

59 CCR4) antibody approved for the treatment of mycosis fungoides and Sezary syndrome.

60 ctor receptor TNFR2, in 18% of patients with mycosis fungoides and Sezary syndrome.

61 subtypes of the disease, the most common are mycosis fungoides and Sezary syndrome.

62 logy of cutaneous T-cell lymphoma, including mycosis fungoides and Sezary syndrome.

63 ous T-cell lymphoma with special emphasis on mycosis fungoides and Sezary syndrome.

64 Mycosis fungoides and the Sezary syndrome represent a he

65 g, prognosis, and treatment of patients with mycosis fungoides and the Sezary syndrome.

66 S) were required to have stage IA-IIIB CTCL (mycosis fungoides and/or Sezary syndrome) and at least >

67 ung, and unknown primary tumors, meningioma, mycosis fungoides, and myeloid leukemia.

68 atients had Sezary syndrome, eight (18%) had mycosis fungoides, and one (2%) had primary cutaneous T-

69 lar lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respe

70 goid, transient acantholytic dermatosis, and mycosis fungoides, and should be considered in elderly p

71 Sezary syndrome and mycosis fungoides are related chronic lymphoproliferativ

72 mas, with particular emphasis on tumor stage mycosis fungoides, as it is in these cases that p53 over

73 PTEN may be important in the pathogenesis of mycosis fungoides, but our data imply that this gene is

74 The most common form of CTCL, mycosis fungoides, can be difficult to diagnose, resulti

75 n vivo chicken embryo model xenografted with mycosis fungoides cells showed that PKCo blockage abroga

76 n vivo chicken embryo model xenografted with mycosis fungoides cells showed that PKCtheta blockage ab

77 on of a number of PKCo target genes found in mycosis fungoides cells significantly correlated with th

78 f a number of PKCtheta target genes found in mycosis fungoides cells significantly correlated with th

79 The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and s

80 Malignant melanoma and mycosis fungoides (cutaneous T cell lymphoma) are rare m

81 Given that mycosis fungoides-cutaneous T-cell lymphoma (MF/CTCL) is

82 from a Macaca nemestrina with CD8(+) T-cell mycosis fungoides-cutaneous T-cell lymphoma.

83 with Sezary syndrome (SS) and erythrodermic mycosis fungoides (e-MF).

84 Thus, lesions clinically suspicious for mycosis fungoides, especially those that have failed chr

85 cutaneous staging system for folliculotropic mycosis fungoides (FMF) has been purported to better est

86 s suggest that patients with folliculotropic mycosis fungoides (FMF) have a worse prognosis than pati

87 aviolet B-related step in the progression of mycosis fungoides from plaque to tumor-stage disease.

88 its total absence in PBLs from patients with mycosis fungoides, inflammatory cutaneous or hematologic

89 Mycosis fungoides is a cutaneous malignancy usually foun

90 0.02%, gel in the treatment of patients with mycosis fungoides is effective and safe.

91 Importantly, mycosis fungoides lesions harbor S. aureus, express Y-ph

92 The most common variant of CTCL, mycosis fungoides (MF ), is confined to the skin in earl

93 mantle cell lymphoma (MCL) (8% [n = 7]), and mycosis fungoides (MF) (9% [n = 8]).

94 ts with relapsed/refractory PTCL (n = 45) or mycosis fungoides (MF) (n = 7).

95 (CTCL) comprising 10 cases with early-stage mycosis fungoides (MF) and 10 cases with late-stage MF o

96 SHV/HHV-8 is involved in the pathogenesis of mycosis fungoides (MF) and related disorders, we used a

97 Transformed mycosis fungoides (MF) and Sezary syndrome (SS) are curr

98 Mycosis fungoides (MF) and Sezary syndrome (SS) are the

99 ective retinoid that can induce apoptosis of mycosis fungoides (MF) and Sezary syndrome (SS) cells.

100 Advanced mycosis fungoides (MF) and Sezary syndrome (SS) have a p

101 umor, node, metastases (TNM) system used for mycosis fungoides (MF) and Sezary syndrome (SS) is not a

102 CD30 expression of malignant lymphocytes in mycosis fungoides (MF) and Sezary syndrome (SS) is quite

103 p of neoplasms originating in the skin, with mycosis fungoides (MF) and Sezary syndrome (SS) represen

104 ogy and diagnostic techniques as pertains to mycosis fungoides (MF) and Sezary syndrome (SS) since th

105 ic treatment options exist for patients with mycosis fungoides (MF) and Sezary syndrome (SS), but no

106 MTAP in cutaneous T-cell lymphoma subgroups, mycosis fungoides (MF) and Sezary syndrome (SS), is unkn

107 Mycosis fungoides (MF) and Sezary syndrome (SS), the maj

108 treatment of CTCL, with specific emphasis on mycosis fungoides (MF) and Sezary syndrome (SS).

109 Many driver genes are shared by mycosis fungoides (MF) and Sezary syndrome (SS).

110 body against CCR4 approved for treatment for mycosis fungoides (MF) and Sezary syndrome (SS).

111 months) in heavily pretreated patients with mycosis fungoides (MF) and Sezary syndrome (SS).

112 xyadenosine (2-CdA) therapy in patients with mycosis fungoides (MF) and the Sezary syndrome (SS).

113 Sezary syndrome (SS) and tumor-stage mycosis fungoides (MF) are generally incurable with curr

114 Neoplastic T cells in mycosis fungoides (MF) are resistant to apoptotic agents

115 Early-stage mycosis fungoides (MF) has been associated with long sur

116 Mycosis fungoides (MF) is a cutaneous T-cell lymphoma ch

117 Mycosis fungoides (MF) is a low-grade lymphoma of cluste

118 Large cell transformation (LCT) in mycosis fungoides (MF) is generally associated with an a

119 Mycosis fungoides (MF) is the most common form of cutane

120 Mycosis fungoides (MF) is the most common form of cutane

121 Mycosis fungoides (MF) is the most common primary cutane

122 Mycosis fungoides (MF) is the most common primary cutane

123 Mycosis fungoides (MF) is the most common subtype of cut

124 orders originating in the skin, among which, mycosis fungoides (MF) is the most common subtype.

125 Mycosis fungoides (MF) is the most frequent form of cuta

126 Mycosis fungoides (MF) is the most frequent manifestatio

127 Although mycosis fungoides (MF) is typically an indolent disease,

128 Although mycosis fungoides (MF) may arise through persistent anti

129 e cell lymphoma (ALCL) of 2 patients and the mycosis fungoides (MF) of 2 other patients.

130 homa, whereas its expression and function in mycosis fungoides (MF) remain ambiguous.

131 uced type I IFN gene expression in untreated mycosis fungoides (MF) skin lesions compared with that i

132 hrough stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical respon

133 Because patients with mycosis fungoides (MF) usually do not have such antibodi

134 ND1/BCL1 expression in 18 of 30 SS, 10 of 23 mycosis fungoides (MF), and three of 10 primary cutaneou

135 patients with the cutaneous T-cell lymphoma, mycosis fungoides (MF), are seronegative for human T-cel

136 catter T (T(HS)) cells were CD4(+) in CD4(+) mycosis fungoides (MF), CD8(+) in CD8(+) MF, and contain

137 The histopathologic diagnosis of mycosis fungoides (MF), even when clinical manifestation

138 common subtype of cutaneous T-cell lymphoma, mycosis fungoides (MF), is characterized by proliferatio

139 mphoma (CTCL), including Sezary syndrome and mycosis fungoides (MF), is poor.

140 sis of the cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), is unclear.

141 (CTCL) may present with eczematous lesions, mycosis fungoides (MF), or as exfoliative erythroderma w

142 patients with a diagnosis of CTCL, including mycosis fungoides (MF), Sezary syndrome (SS), or CTCL no

143 Mycosis fungoides (MF), the most common cutaneous T-cell

144 The pathogenesis of mycosis fungoides (MF), the most common cutaneous T-cell

145 nt lymphocytes from Sezary syndrome (SS) and mycosis fungoides (MF), the most common subtypes of cuta

146 f inflammatory cytokines in 12 patients with mycosis fungoides (MF), the most common variant of CTCL.

147 e retrospectively diagnosed with preexistent mycosis fungoides (MF).

148 a worse prognosis than patients with classic mycosis fungoides (MF).

149 A skin biopsy confirmed mycosis fungoides (MF).

150 explored this strategy in a second disease: mycosis fungoides (MF).

151 proliferative disorders (CD30CLPD) and early mycosis fungoides (MF).

152 SS) and primarily cutaneous variants such as mycosis fungoides (MF).

153 od lymphocyte cultures from 19 patients with mycosis fungoides (MF)/Sezary syndrome (SS) stimulated w

154 Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sezary syndr

155 ients with treatment refractory CD4(+) CTCL (mycosis fungoides [MF], n = 38; Sezary syndrome [SS], n

156 .1% in Sezary syndrome (n = 17) and 28.6% in mycosis fungoides (n = 21).

157 oma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n

158 osity was found in over 10% of patients with mycosis fungoides on 9p, 10q, 1p, and 17p and was presen

159 e enrolled adult patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large-

160 s had anaplastic large-cell lymphoma, 15 had mycosis fungoides or Sezary syndrome (14 with large-cell

161 id) in persistent, progressive, or recurrent mycosis fungoides or Sezary syndrome (MF/SS) cutaneous t

162 ve therefore studied 76 patients with either mycosis fungoides or Sezary syndrome for abnormalities o

163 uppression, such that patients with advanced mycosis fungoides or Sezary syndrome have been compared

164 Among the 8 pivotal trials supporting new mycosis fungoides or Sezary syndrome systemic therapies

165 solid tumours were screened, 35 of whom with mycosis fungoides or Sezary syndrome were enrolled and r

166 We identified 17 patients with mycosis fungoides or Sezary syndrome who either were int

167 ions in patients with relapsed or refractory mycosis fungoides or Sezary syndrome, suggesting it has

168 utaneous T-cell lymphoma (CTCL), or subtypes mycosis fungoides or Sezary syndrome, who had received n

169 nd translational results among patients with mycosis fungoides or Sezary syndrome.

170 A abnormalities in 65 patients with advanced mycosis fungoides or Sezary syndrome.

171 DLBCL: OR(allelic) = 1.12, P(trend) = 0.006; mycosis fungoides: OR(allelic) = 1.44, P(trend) = 0.015)

172 haracteristically slow, we hypothesized that mycosis fungoides originates from an accumulation of lym

173 In the subset of patients with mycosis fungoides, P53 mutations were identified in six

174 bility, a study on specimens of relatives of mycosis fungoides patients (MFR) was begun.

175 quence of hMLH1 promoter hypermethylation in mycosis fungoides patients and may prevent transcription

176 in 21/35 (60%) SS patients and in 3/8 (38%) mycosis fungoides patients, all of whom had clonal blood

177 Sezary syndrome and 5 with rapidly enlarging mycosis fungoides plaques or tumors.

178 Fifty-one mycosis fungoides samples were analyzed for microsatelli

179 elated with that of PRKCQ (PKCo) in 81 human mycosis fungoides samples.

180 ed with that of PRKCQ (PKCtheta) in 81 human mycosis fungoides samples.

181 Eligibility included mycosis fungoides, Sezary syndrome, or primary cutaneous

182 utaneously accessible relapsed or refractory mycosis fungoides, Sezary syndrome, or solid tumours.

183 , 2017, and March 31, 2020, 66 patients with mycosis fungoides, Sezary syndrome, other CTCL, or solid

184 ll documented in a subgroup of patients with mycosis fungoides/Sezary syndrome (MF/SS).

185 A PKCo-dependent transcriptome in mycosis fungoides/Sezary syndrome cells revealed potenti

186 A PKCtheta-dependent transcriptome in mycosis fungoides/Sezary syndrome cells revealed potenti

187 BMC is not due to an intrinsic defect in the mycosis fungoides/Sezary syndrome patients' immune acces

188 ns and outcomes of a subset of patients with mycosis fungoides/Sezary syndrome who were treated with

189 d cases of cutaneous T cell lymphoma (CTCL) (mycosis fungoides/Sezary syndrome) undergo large cell tr

190 ould address an unmet need for patients with mycosis fungoides/Sezary syndrome, a set of incurable di

191 f 31 cutaneous T-cell lymphoma (CTCL) cases (mycosis fungoides/Sezary syndrome, SS) as well as in 5 o

192 e-agent lenalidomide in advanced, refractory mycosis fungoides/Sezary syndrome.

193 oportion of cutaneous T-cell lymphoma (CTCL)/mycosis fungoides skin samples and in one melanoma.

194 ients with Sezary syndrome (SS), transformed mycosis fungoides (T-MF), and cutaneous anaplastic large

195 sect key pathological features implicated in mycosis fungoides, the most common cutaneous T-cell lymp

196 evels of TOX were significantly increased in mycosis fungoides, the most common type of cutaneous T-c

197 We also included tissue from two cases of mycosis fungoides, three normal skin biopsies, and three

198 iptomics analysis of skin from patients with mycosis fungoides-type CTCL and an integrated comparativ

199 Eighteen cases of early mycosis fungoides were compared with 18 cases of eczemat

200 that only 60% of the deaths attributable to mycosis fungoides were so certified.

201 erythroderma or Sezary syndrome and 11 with mycosis fungoides, were studied for the occurrence of st

202 oss on 1p and 9p were found in all stages of mycosis fungoides, whereas losses on 17p and 10q were li

203 In total, 260 patients with stage IA to IIA mycosis fungoides who had not used topical mechlorethami

204 MSI and disease progression in patients with mycosis fungoides, with 6 of 15 (40%) patients with MSI